Seasonal influenza vaccine uptake among patients with cardiovascular disease in Denmark, 2017-2019
- PMID: 35953403
- PMCID: PMC10405130
- DOI: 10.1093/ehjqcco/qcac049
Seasonal influenza vaccine uptake among patients with cardiovascular disease in Denmark, 2017-2019
Abstract
Background: Influenza vaccination protects against morbidity and mortality in patients with cardiovascular disease (CVD). We aimed to describe influenza vaccine uptake in patients with CVD in a universal-access healthcare system.
Methods: Using nationwide Danish registries, we included all patients with prevalent CVD, defined as heart failure (HF), atrial fibrillation (AF), ischemic heart disease (IHD), or stroke during three consecutive influenza seasons (October-December 2017-2019). The outcome was relative frequency of influenza vaccination across strata of patient characteristics.
Results: There was an average of 397 346 patients with CVD yearly during 2017-2019. Vaccine uptake was 45.6% for the whole population and ranged from 55.0% in AF to 61.8% in HF among patients aged ≥65 years. Among patients aged <65 years, uptake was 32.6% in HF, 19.0% in AF, 21.1% in IHD, and 18.3% in stroke. There was a lower uptake with decreasing age: 21.6% in HF, 5.5% in AF, 7.4% in IHD, and 6.3% in stroke among males aged <45 years, as opposed to 25.5% in HF, 11.5% in AF, 13.8% in IHD, and 12.1% in stroke for males aged 45-54 years. In the further stratified analyses, uptake ranged from a low of 2.5% for males <45 years with AF who were not vaccinated the previous season to a high of 87.0% for females ≥75 years with IHD who were vaccinated the previous season.
Conclusion: Seasonal influenza vaccine uptake is suboptimal among patients with CVD, even in a universal-access healthcare system with free-of-charge vaccinations. Vaccine uptake was particularly low among young patients.
Keywords: Cardiovascular; Influenza; Registry; Vaccine.
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.
Conflict of interest statement
Dr Tor Biering-Sørensen reports the following: Steering Committee member of the Amgen financed GALACTIC-HF trial; Chief investigator and steering committee chair of the Sanofi Pasteur financed ‘NUDGE-FLU’ trial; Chief investigator and steering committee chair of the Sanofi Pasteur financed ‘DANFLU-1’ trial; Chief investigator and steering committee chair of the Sanofi Pasteur financed ‘DANFLU-2’ trial; Steering Committee member of ‘LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System’ trial; Advisory Board: Sanofi Pasteur, Amgen and GSK; Speaker Honorarium: Novartis, Sanofi Pasteur and GSK; Research grants: GE Healthcare and Sanofi Pasteur. Dr Christian Torp-Pedersen reports the following: Grants for studies from Bayer and Novo Nordisk unrelated to the current study. Dr Schou reports lecture fees from Novo Nordisk, Astra Zeneca, Novartis, and Boehringer Ingelheim outside the current study. All other authors had no conflicts of interest to disclose.
Figures




Similar articles
-
Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study.Diabetes Care. 2020 Sep;43(9):2226-2233. doi: 10.2337/dc20-0229. Epub 2020 Jul 9. Diabetes Care. 2020. PMID: 32647052
-
Effect of Electronic Nudges on Influenza Vaccination Rate in Older Adults With Cardiovascular Disease: Prespecified Analysis of the NUDGE-FLU Trial.Circulation. 2023 May 2;147(18):1345-1354. doi: 10.1161/CIRCULATIONAHA.123.064270. Epub 2023 Mar 5. Circulation. 2023. PMID: 36871213 Clinical Trial.
-
Electronic nudges to increase influenza vaccination uptake among patients with heart failure: A pre-specified analysis of the NUDGE-FLU trial.Eur J Heart Fail. 2023 Aug;25(8):1450-1458. doi: 10.1002/ejhf.2913. Epub 2023 Jun 4. Eur J Heart Fail. 2023. PMID: 37211967
-
Determinants of Influenza Vaccine Uptake in Patients With Cardiovascular Disease and Strategies for Improvement.J Am Heart Assoc. 2021 Aug 3;10(15):e019671. doi: 10.1161/JAHA.120.019671. Epub 2021 Jul 28. J Am Heart Assoc. 2021. PMID: 34315229 Free PMC article. Review.
-
Cardioprotective effects of influenza vaccination among patients with established cardiovascular disease or at high cardiovascular risk: a systematic review and meta-analysis.Eur J Prev Cardiol. 2022 Oct 20;29(14):1881-1892. doi: 10.1093/eurjpc/zwac152. Eur J Prev Cardiol. 2022. PMID: 35857821
Cited by
-
Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review.J Clin Med. 2024 May 21;13(11):3029. doi: 10.3390/jcm13113029. J Clin Med. 2024. PMID: 38892740 Free PMC article. Review.
References
-
- Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow Tet al. . Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med 2018;378:345–353. - PubMed
-
- Ciszewski A, Bilinska ZT, Brydak LB, Kepka C, Kruk M, Romanowska Met al. . Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J 2008;29:1350–1358. - PubMed
-
- Modin D, Jørgensen ME, Gislason G, Jensen JS, Køber L, Claggett Bet al. . Influenza vaccine in heart failure. Circulation 2019;139:575–586. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous